Episode Details
Back to Episodes
Mar 3, 2026 | Novo’s $506M Oral GLP-1 Manufacturing Bet, Sotyktu PsA PDUFA Friday, Orforglipron Race Begins
Published 4 months, 3 weeks ago
Description
Novo Nordisk commits €432 million ($506M) to expand oral semaglutide tablet manufacturing in Athlone,Ireland — a supply bet on oral Wegovy’s trajectory as 246,000 patients are already on therapy. Morgan Stanley upgrades Novo from Underweight to Equal Weight,citing ~56% potential upside as a floor call, while Lilly holds a 21-point GLP-1 market share lead (60.5% vs 39.1%). Orforglipron’s Q2 FDA decision is the next test of whether Novo can hold the oral lane. BMS has a PDUFA on Friday for Sotyktu’s psoriatic arthritis indication — which would make deucravacitinib the first TYK2 inhibitor approved in PsA. Imcivree (March 20) and Kresladi (March 28) PDUFA dates round out a busy Q1 regulatory calendar.